Topic 1 | Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD |
Topic 2 | Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS |
Topic 3 | Beyond antiangiogenesis: What are the options?
Andres Poveda, MD |
|
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.